EUCTR2012-002535-28-PT进行中（未招募）1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RA
Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London0 个研究点目标入组 160 人开始时间: 2014年2月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be recruited with active RA:
- •1. Patients who have failed anti-TNF therapy (inadequate responders – ir). Note: this includes patients that have failed anti-TNF therapy because of reactions.
- •2. Who are eligible for Rituximab therapy according NICE guidlines
- •3. Patients should be receiving a stable dose Methotrexate for at least 4 weeks prior to the biopsy visit.
- •4. 2010 ACR / EULAR Rheumatoid Arthritis classification criteria for a diagnosis of Rheumatoid Arthritis.
- •5. Over 18 years of age
- •6. Patient must be capable of giving informed consent
- •7. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1.Women who are pregnant or breast-feeding
- •2.Women of child-bearing potential, or males whose partners are women of child-bearing potential, unwilling to use effective contraception during the study and for at least 12 months after stopping study treatment.
- •3.History of or current primary inflammatory joint disease, or primary rheumatological autoimmune disease other than RA (if secondary to RA, then the patient is still eligible).
- •4.Prior exposure to Rituximab or Tocilizumab for the treatment of RA
- •5.Treatment with any investigational agent = 4 weeks prior to baseline (or < 5 half- lives of the investigational drug, whichever is the longer).
- •6.Intra articular or parenteral corticosteroids = 4 weeks prior to biopsy visit (Visit 2)
- •7.Oral prednisolone more than 10mg per day or equivalent = 4 weeks prior to biopsy visit (Visit 2)
- •8.Active infection.
- •9.Septic arthritis within a native joint within the last 12 months.
- •10.Sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ.
- •11.Known HIV or active hepatitis B/C infection. Hepatitis B screening test must be performed at or in the preceding 3 months of screening visit.
- •12.Latent TB infection unless they have completed adequate antibiotic prophylaxis.
- •13.Malignancy (other than basal cell carcinoma) within the last 10 years
- •14.New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure.
- •15.Demyelinating disease.
- •16.Latex allergy or allergy to any excipients of Rituximab or Tocilizumab
- •17.Any other contra-indication to the study medications as detailed in their summaries of product characteristics (SmPC), including low IgG levels at clinician’s discretion.
- •18.Receipt of live vaccine <4 weeks prior to first infusion
- •19.Major surgery in 3 months prior to first infusion
- •20.Presence of a transplanted organ (with the exception of a corneal transplant >3 months prior to screening)
- •21.Known recent substance abuse (drug or alcohol)
- •22.Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period.
- •23.Patients unable to tolerate synovial biopsy or in whom this is contraindicated including(e.g. patients on anti-coagulants (oral anti-platelet agents are permitted)).
- •24.Patients currently recruited to other clinical trial(s) involving an investigational medicinal product (except any observational follow-up periods not involving an IMP).trials.
- •25.Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RARheumatoid ArthritisEUCTR2012-002535-28-BEJoint Research & Development Office (Barts and The London School of Medicine & Dentistry)160
进行中（未招募）
1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)MedDRA version: 18.0Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859Rheumatoid ArthritisEUCTR2012-002535-28-ESJoint Research & Development Office (Barts and The London School of Medicine & Dentistry)180
进行中（未招募）
1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RAMedDRA version: 17.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859Rheumatoid ArthritisEUCTR2012-002535-28-ITJoint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London164
进行中（未招募）
1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA) - R4-RAMedDRA version: 20.0Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859Rheumatoid ArthritisEUCTR2012-002535-28-GBJoint Research & Development Office (Barts and The London School of Medicine & Dentistry)164
进行中（未招募）
1 期
A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)MedDRA version: 19.0Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859Rheumatoid ArthritisEUCTR2012-002535-28-NLJoint Research & Development Office (Barts and The London School of Medicine & Dentistry)164